BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12836810)

  • 1. Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension.
    Fanghänel G; Cortinas L; Sánchez-Reyes L; Gómez-Santos R; Campos-Franco E; Berber A
    Adv Ther; 2003; 20(2):101-13. PubMed ID: 12836810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity.
    Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
    Int J Obes Relat Metab Disord; 2000 Feb; 24(2):144-50. PubMed ID: 10702763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
    Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
    Scholze J; Grimm E; Herrmann D; Unger T; Kintscher U
    Circulation; 2007 Apr; 115(15):1991-8. PubMed ID: 17404163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
    Cuellar GE; Ruiz AM; Monsalve MC; Berber A
    Obes Res; 2000 Jan; 8(1):71-82. PubMed ID: 10678261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.
    McMahon FG; Fujioka K; Singh BN; Mendel CM; Rowe E; Rolston K; Johnson F; Mooradian AD
    Arch Intern Med; 2000 Jul; 160(14):2185-91. PubMed ID: 10904462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of sibutramine in obese Hispanic adolescents.
    Violante-Ortìz R; Del-Rio-Navarro BE; Lara-Esqueda A; Pèrez P; Fanghänel G; Madero A; Berber A
    Adv Ther; 2005; 22(6):642-9. PubMed ID: 16510381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
    Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
    Int J Obes Relat Metab Disord; 2001 May; 25(5):741-7. PubMed ID: 11360159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
    Gaciong Z; Placha G
    J Hum Hypertens; 2005 Sep; 19(9):737-43. PubMed ID: 15905888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients.
    Hazenberg BP
    Cardiology; 2000; 94(3):152-8. PubMed ID: 11279320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced left ventricular mass after treatment of obese patients with sibutramine: An echocardiographic multicentre study.
    Wirth A; Scholze J; Sharma AM; Matiba B; Boenner G
    Diabetes Obes Metab; 2006 Nov; 8(6):674-81. PubMed ID: 17026492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.
    Maggioni AP; Caterson I; Coutinho W; Finer N; Gaal LV; Sharma AM; Torp-Pedersen C; Bacher P; Shepherd G; Sun R; James P;
    J Cardiovasc Pharmacol; 2008 Nov; 52(5):393-402. PubMed ID: 19033818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure.
    Birkenfeld AL; Schroeder C; Pischon T; Tank J; Luft FC; Sharma AM; Jordan J
    Clin Auton Res; 2005 Jun; 15(3):200-6. PubMed ID: 15944869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A randomized, double-blind, placebo-controlled, multicenter study on sibutramine in over-weighted and obese subjects].
    Zhao Y; Wang X; Yan Z
    Zhonghua Yu Fang Yi Xue Za Zhi; 2001 Sep; 35(5):329-32. PubMed ID: 11769634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy.
    Serrano-Rios M; Melchionda N; Moreno-Carretero E;
    Diabet Med; 2002 Feb; 19(2):119-24. PubMed ID: 11874427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.